Freudenberg Medical expands coatings business with $50 M investment in new production facility in Germany

Freudenberg Medical, a global contract design and manufacturing (CDMO) partner to the medical device and biopharma industry with facilities in key industry hubs across the Americas, Europe and Asia, has announced plans to further expand its drug device combination products business.

The company is investing more than $50 million in a new Hemoteq AG production facility in Aachen, Germany, one of the most important life science hotspots in Europe.

Through the acquisition of Hemoteq in 2015, Freudenberg Medical expanded its portfolio to include drug coating solutions for balloon catheters and stents as well as hydrophilic coatings.

The company will triple its manufacturing footprint with the new 130,000 sq. ft. facility in Alsdorf, located near the existing site. With its ISO Class 7 cleanrooms, laboratories, and offices it will serve as a hub for research, development, and production, driving innovation in medical coatings.

The predicted global market value of drug device combination products is $180 billion annually by the end of the decade. 

The first employees have been working at the new site since April 2024 in a development cleanroom adjacent to the main building. The site will be fully occupied by the end of 2026. Recruitment for the 150 additional positions in operations and R&D has already begun. With a total area of 440,000 sq. ft., the site offers space for future expansion to reliably serve customers with advanced medical coatings.